AR and prostate neoplasm: Enzalutamide, a popular antiandrogen drug, inhibits the growth of castrate-resistant prostate tumors, not only by blocking androgen binding to the AR but also by obstructing AR nuclear translocation, DNA binding, and co-activator recruitment (130).